Goldman Sachs Maintains Buy on Beta Bionics, Lowers Price Target to $20
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Goldman Sachs analyst David Roman maintains Beta Bionics (NASDAQ:BBNX) with a Buy and lowers the price target from $23 to $20.
Goldman Sachs analyst David Roman maintains Beta Bionics (NASDAQ:BBNX) with a Buy and lowers the price target from $23 to $20.